Join Now
Sign In
Anas Younes, MD
AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified) )| Communities: Non-Hodgkin Lymphoma , Hodgkin Lymphoma , Myeloma | Answers: 7 |
| Member Since: Jun. 2012 |
Ask AnasYounesMD a question:
0
Cc:
Twitter
Facebook
Professional Statement
Dr. Anas Younes is Professor and Director of the Clinical and Translational Research Program in the Department of Lymphoma/Myeloma, Division of Cancer Medicine at M. D. Anderson Cancer Center in Houston, Texas.
He completed his medical degree at the The University of Damascus School of Medicine followed by postgraduate training at Memorial Sloan-Kettering Cancer Center, The State University of New York - Downstate Medical Center, Medical College of Ohio and the NICHD National Institutes of Health. Dr. Younes is board certified by the American Board of Medical Oncology and the American Board of Internal Medicine. He is a member of several professional organizations, including American Society of Clinical Oncology, the American Society of Hematology and the Lymphoma Research Foundation.
He completed his medical degree at the The University of Damascus School of Medicine followed by postgraduate training at Memorial Sloan-Kettering Cancer Center, The State University of New York - Downstate Medical Center, Medical College of Ohio and the NICHD National Institutes of Health. Dr. Younes is board certified by the American Board of Medical Oncology and the American Board of Internal Medicine. He is a member of several professional organizations, including American Society of Clinical Oncology, the American Society of Hematology and the Lymphoma Research Foundation.
Professional Info
Credential: MD
Primary specialty: Oncology - Hematology/Oncology
Medical school: The University of Damascus School of Medicine
Residency: State University of New York, Downstate Medical Center; Medical College of Ohio
Fellowship: Memorial Sloan-Kettering Cancer Center
Hospital affiliation: MD Anderson Cancer Center
Practice address:
1515 Holcombe Boulevard - Unit 429 Unit Number: 429
Houston, TX
77030
Practice phone number: 713/794-5656
Twitter
https://twitter.com/DrAnasYounes
AnasYounesMD Activities
Patients who receive autologous stem cell transplant usually have an average hospital stay of 10-14 days. The average hospital stay is a bit longer for allogeneic transplant patients.
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
During treatment, patients usually have blood tests before each treatment. Imaging studies are usually repeated every 2-3 months to ensure response to therapy.
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
Patients whose disease does not respond to or relapse after treatment with ABVD usually receive a second-line combination therapy that contain platinum or gemcitabine, followed by stem cell transplant
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
ABVD combination chemotherapy is the most widely used regimen for the treatment of classical HL.
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
Classical HL typically express CD30 receptor, and therefore, can be treated with brentuximab vedotin. It is highly curable type with combination of chemotherapy and radiation therapy.
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
The major subtypes of HL are the classical type (95%) and the lymphocyte predominant type (5%).
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
This is the first antibody-drug-conjugate approved for lymphoma, and the first drug approved for HL in more than 30 years. Because brentuximab vedotin precisely delivers the toxic drug to tumor cells, it has very fewer side effects compared with traditional chemotherapy drugs.
New answer by AnasYounesMD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
AnasYounesMD's Profile
Newsletters
Sign up for email updates of the latest news, best answers, and featured experts.
Benefits
Custom health, wellness, & medical offers including clinical trials, market research opportunities, & new programs.
Share TalkAboutHealth
To share TalkAboutHealth with friends, type their email addresses here (separated by commas):
From:
Add a personal note here:
Please join TalkAboutHealth and you will be able to ask questions.
Your question to AnasYounesMD:
2) Background Info (optional): What context or background information is relevant to this request?
Notes:
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
Newsletters
